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Th17 cells, CD4+ T cells that secrete interleukin-17
(IL-17), are pathogenic in autoimmune diseases and
their development and expansion is driven by the
cytokines IL-6, TGF-b, IL-21, IL-1, and IL-23.
However, there are also innate sources of IL-17.
Here, we show that gd T cells express IL-23R and
the transcription factor RORgt and produce IL-17,
IL-21, and IL-22 in response to IL-1b and IL-23,
without T cell receptor engagement. IL-17-producing
gd T cells were found at high frequency in the brain of
mice with experimental autoimmune encephalomy-
elitis (EAE). gd T cells activated by IL-1b and IL-23
promoted IL-17 production by CD4+ T cells and
increased susceptibility to EAE, suggesting that gd
T cells act in an amplification loop for IL-17 produc-
tion by Th17 cells. Our findings demonstrate that gd
T cells activated by IL-1b and IL-23 are an important
source of innate IL-17 and IL-21 and provide an alter-
native mechanism whereby IL-1 and IL-23 may
mediate autoimmune inflammation.
INTRODUCTION
Th17 cells, CD4+ T cells that secrete interleukin-17 (IL-17), play
a critical role in inflammatory pathology in organ-specific autoim-
mune diseases, including multiple sclerosis (MS) and rheuma-
toid arthritis, a role hitherto attributed to Th1 cells (Harrington
et al., 2005; Koenders et al., 2005; Langrish et al., 2005; Park
et al., 2005). Furthermore, Th17 cells play a role in immunity to
infection, for which they are generated through induction of
innate cytokines via activation of Toll-like receptors (TLRs) and
NOD-like receptors (NLRs) (Higgins et al., 2006; Veldhoen
et al., 2006). IL-6 and transforming growth factor (TGF)-b can
induce the differentiation of naive murine T cells into Th17 cells
(Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al.,
2006). IL-21 is also a key cytokine in the differentiation of murine
and human CD4+ Th17 cells, in which it appears to act in an
autocrine loop involving TGF-b or IL-23 (Korn et al., 2007;
Nurieva et al., 2007; Yang et al., 2008; Zhou et al., 2007).IL-23p19-deficient (Il23a/) mice are resistant to the induc-
tion of experimental autoimmune encephalomyelitis (EAE) (Cua
et al., 2003), and IL-23 was initially thought to be the critical cyto-
kine in the differentiation of Th17 cells. However, naive murine
T cells do not express IL-23R and do not differentiate into
Th17 cells in response to IL-23 in vitro (Langrish et al., 2005;
van Beelen et al., 2007). In contrast, IL-23 can expand Th17 cells
from memory CD4+ T cells (Aggarwal et al., 2003). We have also
demonstrated that IL-1a or IL-1b synergizes with IL-23 to
promote IL-17 production by murine T cells in the presence or
absence of T cell receptor engagement (Sutton et al., 2006).
Furthermore, IL-17 production and development of EAE is
compromised in IL-1 receptor type I-defective (Il1r1/) mice.
IL-1 and IL-23 promote IL-17 production by memory but not
naive T cells (van Beelen et al., 2007). However, it has recently
been reported that IL-1 signaling is critical for Th17 cell differen-
tiation (Chung et al., 2009). Moreover, our studies, together with
recent reports on human Th17 cells (Manel et al., 2008; Volpe
et al., 2008) and on IL-23-driven innate IL-17 production (Hue
et al., 2006; Takatori et al., 2009), suggest that the function of
IL-23 may not be confined to expansion of memory Th17 cells.
AlthoughCD4+ T cells are considered to be themajor source of
IL-17, especially in autoimmune diseases, recent evidence has
suggested thatotherTcell populationscanproduce IL-17.Murine
CD8+ T cells produce IL-17 in response to conditioned medium
from dendritic cells (DCs) activated with Klebsiella pneumoniae
(Happel et al., 2003). Furthermore, unconventional T cells can
also secrete IL-17 during infection (Lockhart et al., 2006; Shibata
et al., 2007). NKT cells, which express IL-23R, secrete IL-17 after
stimulation with anti-CD3 and IL-23 (Rachitskaya et al., 2008).
gd T cells provide an early source of IFN-g in mucosal tissues
(Lochner et al., 2008; Ivanov et al., 2006) and are pathogenic in
EAE, collagen-induced arthritis (CIA), and colitis models in
mice (Jensen et al., 2008; Nanno et al., 2008; Roark et al.,
2007; Spahn et al., 1999). Their pathogenic role in autoimmunity
was initially thought to be mediated through IFN-g production.
However, recent studies have shown that gd T cells can secrete
IL-17 during infection withMycobacterium tuberculosis (MTB) or
E. coli, in which they promote neutrophil recruitment (Lockhart
et al., 2006; Shibata et al., 2007). Interestingly, it has recently
been shown that IL-17 production by gd T cells is independent
of IL-6 (Lochner et al., 2008), an essential cytokine for driving
the development of Th17 cells.Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc. 331
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gd T Cells Are an Important Source of Innate IL-17In this study, we address the hypothesis that gd T cells may
secrete innate IL-17 in response to IL-1 and IL-23. We found
that gd T cells expressed IL-23R and that stimulation with IL-1
and IL-23 promoted RORgt, IL-17A, IL-17F, IL-21, and IL-22
expression by gd T cells in the absence of T cell receptor (TCR)
engagement. Furthermore, IL-17-secreting gd T cells were
present at high frequency in the central nervous system (CNS)
of mice with EAE, in which they functioned with CD4+ Th17 cells
to mediate autoimmune pathology.
RESULTS
IL-1b and IL-23 Promote IL-17 Production by
Unconventional T Cells in the Absence of TCRActivation
Consistent with previous reports on the roles of IL-6 with TGF-b
and IL-1b with IL-23 in promoting IL-17 production by naive and
memory T cells, respectively, we found that both of these cyto-
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B Figure 1. IL-1b and IL-23 Promote IL-17
Production by CD3+ but Not by CD4+ or
CD8+ T Cells in the Absence of TCR Engage-
ment
(A) Spleen cells from C57BL/6 or Il1r1/ mice
were stimulated with IL-1b and/or IL-23 with and
without anti-CD3 for 3 days. IL-17 concentrations
in supernatants were quantified by ELISA. **p <
0.01 and ***p < 0.001, versus C57BL/6.
(B) Spleen cells from C57BL/6 mice were stimu-
lated as indicated without anti-CD3 for 3 days and
stained for intracellular IL-17 and for surface CD3.
Numbers refer to percentages of CD3+IL-17+ cells.
(C) Spleen cells, CD4+ T cells, or CD4+CD62LhiC-
D44lo T cells from C57BL/6 mice were stimulated
for 3 days as indicated. IL-17 concentrations
were quantified by ELISA. **p < 0.01 and ***p <
0.001, versus medium control.
(D) Spleen cells from C57BL/6 mice were cultured
for 3 days with medium only or IL-1b and IL-23,
and intracellular IL-17 was determined in CD3,
CD4, or CD8 cells. Numbers refer to percentages
of IL-17+ cells. Results for ELISA data are
means ± SE of triplicate culture and representative
of three experiments. All error bars represent
mean ± SD.
kine combinations induced IL-17 produc-
tion by murine spleen cells after stimula-
tion with anti-CD3. In contrast, IL-6 and
TGF-b failed to induce IL-17 production
in the absence of TCR activation
(Figure 1A), whereas IL-17 was produced
by spleen cells stimulated with IL-23 and
IL-1b in the absence of anti-CD3. Further-
more, in the presence of anti-CD3, IL-17
production in response to IL-23 and
IL-1b, but also in response to IL-6 and
TGF-b, was substantially reduced in
spleen cells from Il1r1/ mice, demon-
strating the critical role of IL-1 signaling
in IL-17 production. IL-17 protein produc-
tion was assessed after 72 hr, but was
detectable at low amounts after 48 hr (Sutton et al., 2006) and
was maximal in the region of 10 ng/ml of IL-1b and IL-23 (data
not shown), a concentration that was used for subsequent exper-
iments. Intracellular cytokine staining (ICS) confirmed that IL-1b
and IL-23, but not IL-6 and TGF-b, induced IL-17 production by
CD3+ T cells in the absence of anti-CD3 (Figure 1B). When acti-
vatedwith anti-CD3andanti-CD28, IL-1band IL-23 failed to stim-
ulate IL-17 production by naive (CD4+CD62LhiCD44lo) T cells but
did promote IL-17 production by total CD4+ T cells (Figure 1C).
Furthermore, ICS demonstrated that, in the absence of anti-
CD3, IL-1b and IL-23 induced IL-17 secretion by CD3+ T cells,
but not by CD4+ or CD8+ T cells (Figure 1D). These findings
demonstrate that unconventional CD3+CD4CD8 T cells, but
not conventional CD4+ or CD8+ T cells, secrete IL-17 in response
to IL-1b and IL-23 in the absence of TCR engagement.
A current view on the generation of IL-17-producing T cells
in vivo is that innate IL-6 and TGF-b promote development,332 Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc.
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gd T Cells Are an Important Source of Innate IL-17whereas IL-1 and IL-23 enhance the expansion of Th17 cells, and
that these innate cytokines are induced in response to pathogen-
associated molecular patterns (PAMPs), including TLR and NLR
agonists. Here, we examined the role of TLR and NLR-induced
IL-1 and IL-23 production by DCs in promoting innate IL-17
production by T cells. Stimulation of DC with TLR and NLR
agonists (Figure 2A) or with killed MTB (Figure 2B) induced
high concentrations of IL-1b, IL-23, and IL-6, but interestingly
no IL-12p70. Furthermore, in the absence of anti-CD3, CD3+
T cells cultured with DC that had been simulated with MTB
(Figure 2C) or TLR and NLR agonists (Figure S1 available online),
induced IL-17 production, which was blocked by IL-1 receptor
antagonist (IL-1Ra) and partially blocked by anti-IL-23R. These
findings demonstrate that PAMP-activated IL-1b and IL-23
promote innate IL-17 production by T cells in the absence of
TCR activation.
IL-1b and IL-23 Induce IL-17 and IL-21 Expression
in gd T Cells in the Absence of TCR Engagement
Having demonstrated that CD3+ but not CD4+ or CD8+ T cells
secrete IL-17 in response to IL-1b and IL-23, in the absence of
stimulation with anti-CD3 or anti-CD28, we sought to identify
the T cell population responsible for the innate IL-17 production.
We found that depletion of gd T cells significantly (p < 0.001)
reduced the production of IL-17 by CD3+ T cells in response to
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Figure 2. Killed M. tuberculosis or Purified TLR and NLR Agonists
Induce Innate IL-17 Production by T Cells by Stimulating DC IL-23
and IL-1b Production
(A and B) Murine bone marrow-derived DCs were incubated with LPS, MDP,
PGN, LPS + PGN, MDP + PGN or with medium alone (A), or with killed MTB
(B). Supernatants were removed after 24 hr and IL-23, IL-1b, IL-12p70, and
IL-6 concentrations quantified by ELISA.
(C) DCs were stimulated with MTB or medium only for 24 hr, washed, and
added to CD3+ T cells with IL-1Ra, anti-IL-23R, both, or a control antibody
(not shown). After 3 days, IL-17 was quantified in the supernatants by ELISA.
*p < 0.05 and **p < 0.01, versus MTB alone. Data are means for triplicate
cultures and are representative of two experiments. All error bars represent
mean ± SD.IL-1b and IL-23, in the absence of stimulation with anti-CD3
(Figure 3A). Furthermore, IL-17 was barely detectable in spleen
cells frommice defective in gd TCR (Tcrd/), but was produced
by spleen cells from wild-type (WT) mice stimulated with IL-1b
and IL-23 in the absence of anti-CD3 (Figure 3B). Conversely,
purified gd T cells, but not spleen cells depleted of gd T cells,
secreted IL-17 in response to IL-1b and IL-23 (Figure 3C). ICS
confirmed that a substantial proportion of gd T cells secreted
IL-17 in response to IL-1b and IL-23 in the absence of anti-
CD3 (Figure 3D). In contrast, we failed to detect IL-17 production
by NK or NKT cells after stimulation of spleen cells with IL-1b and
IL-23 (not shown).
We next used real-time PCR to confirm the effect of IL-1b and
IL-23 on expression of IL-17 and other cytokines, receptors and
transcription factors associated with Th17 cells. Stimulation
of purified gd T cells with IL-23 induced expression of IL-17A,
IL-17F, and IL-22 mRNA, which was enhanced by addition of
IL-1b, and this was significantly (p < 0.001) higher than that
induced in gd T cell-depleted CD3+ T cells (Figure 3E). IL-21
plays a role in the development of murine CD4+ Th17 cells
(Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007). We
found that IL-1b and IL-23, but neither cytokine alone, promoted
substantial IL-21 expression in gd T cells, but not in CD3+ T cells
depleted of gd T cells (Figure 3E). The transcription factor RORgt
is associated with the development of CD4+ Th17 cells (Ivanov
et al., 2006) and is also expressed by NKT cells (Rachitskaya
et al., 2008). We demonstrate constitutive RORgt expression in
gd T cells, which was enhanced by IL-23 (Figure 3E). It has previ-
ously been reported that IL-23R is expressed on NK cells and
memory T cells (Parham et al., 2002).We found that gd T cells ex-
pressed high constitutive levels of IL-23R, which were enhanced
by stimulation with IL-23 alone or in combination with IL-1b
(Figure 3E). Cell-surface staining and flow cytometry analysis
confirmed that IL-23 promoted IL-23R expression on gd T cells
(Figure 3F). We also examined the capacity for IL-1 and IL-23
to stimulate IL-17 production in vivo. We found substantial
IL-17A and IL-17F gene expression in the draining lymph nodes
4 hr after injection of IL-1 and IL-23 into the footpad (Figure S2A).
Consistent with a previous report (Jensen et al., 2008), ICS
revealed a relatively high frequency of IL-17-producing gd
T cells in lymph nodes of naive mice. We found that this was
enhanced after injection of IL-1 and IL-23 (Figure S2B). These
findings suggest that IL-1 and IL-23 promote rapid IL-17 gene
expression and protein production in vitro and in vivo and that
gd T cells are a source of innate IL-17, but do not rule out other
innate sources of IL-17.
A High Frequency of IL-17-Secreting gd T Cells Infiltrate
the CNS of Mice with EAE
Having shown that gd T cells produce IL-17 in response to stim-
ulation with IL-1b and IL-23, we examined the possibility that
these cells are a source of IL-17 during development of EAE, in
which IL-17 has been shown to play a key role in inflammatory
pathology. We found substantial infiltration of IL-17-secreting
gd T cells into the brain during the course of EAE (Figure 4A).
gd T cells were detectable on day 7 after induction, immediately
prior to onset of clinical signs of EAE, and peaked at day 10–14
and a very high proportion (50%–80%) of these cells secreted IL-
17 (Figures 4A and 4C). In contrast, the frequency of gd T cellsImmunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc. 333
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gd T Cells Are an Important Source of Innate IL-17IL-23
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Figure 3. IL-1b and IL-23 Stimulate IL-17A,
IL-17F, IL-21, IL-22, and IL-23R Expression
by gd T Cells
(A–C) CD3+ T cells and CD3+ T cells depleted of gd
T cells (A), spleen cells from C57BL/6 and Tcrd/
mice (B), purified gd T cells, and gd-depleted
spleen cells from C57BL/6 mice (C) were stimu-
lated for 3 days as indicated. IL-17 concentrations
in supernatants were quantified by ELISA. ***p <
0.001 versus WT or nondepleted.
(D) Spleen cells from C57BL/6 mice were cultured
with IL-1b and IL-23 or medium alone for 3 days,
and intracellular staining was performed for IL-17
and surface gd TCR. Numbers refer to the
percentage of positive cells.
(E) gd-depleted CD3+ T cells or purified gd T cells
were stimulated with medium only, IL-1, IL-23, or
IL-1 and IL-23 both. IL-17A, IL-17F, IL-21, IL-22,
RORgt, and IL-23R mRNA expression was evalu-
ated by real-time PCR normalized to 18 s rRNA
and relative to gd-depleted T cells stimulated with
medium only. *p < 0.05, **p < 0.01, and ***p <
0.001 versus medium control; +p < 0.05, 2+p <
0.01, and +++p < 0.001, versus gd-depleted T cells.
(F) Spleen cells were stimulated with IL-23 or
medium for 24 hr and were then analyzed for
IL-23R expression. Dot plots are shown for staining
with anti-IL-23R and an isotype control antibody.
Numbers on the dot plots indicate the percentage
of gated gd T cells. All data are representative of at
least three independent experiments. All error bars
represent mean ± SD.secreting IFN-g was significantly lower, and there was only
a small increase in their numbers during the course of EAE.
Conversely, the frequency of both CD4+IFN-g+ and CD4+IL-
17+ T cells was enhanced during the development of EAE
(Figure 4B).
gd T cells expressing Vg4+ are expanded in CIA (Roark et al.,
2007). We found that more than 70% of gd T cells in the brain
at the acute phase of EAE were Vg4+ and that more than 50%
of these secreted IL-17 (Figure 4D). We also detected Vg5+ cells
and Vd6.3/2+ cells, but the majority of these were not IL-17
secreting. In the spleen, the overall frequency of IL-17-secreting
gd T cells was lower but over 90% of these were Vg4+
(Figure S3).
We also found elevated IL-17 mRNA expression in the CNS
during development of EAE (Figure 4E). In addition, IL-1b and
IL-23p19 mRNA was enhanced in the spleen 1–7 days after
immunization (data not shown), but was also enhanced in the
CNS at the onset of clinical symptoms (Figure 4E), which coin-
cided with the detection of IL-17-secreting gd T cells in the brain.
These findings demonstrate that gd T cells are an important
source of IL-17 in the CNS during development of EAE and,
together with the data presented in Figure 3, suggest that IL-1
and IL-23 may be an important stimulus for early production of
innate IL-17 during development of EAE.334 Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc.IL-17-Secreting gd T Cells Cooperate
with CD4+ T Cells in the Development of EAE
We next examined the role of gd T cells in the development of the
clinical symptoms of EAE. We found that EAE was less severe in
Tcrd/ mice; the onset of disease was delayed and the clinical
scores were reduced (Figure 5A). This was associated with
significantly (p < 0.01 – p < 0.001) lower MOG-specific IL-17
production by lymph nodes of Tcrd/ mice (Figure 5B), sug-
gesting that gd T cells are required for antigen-specific
responses by conventional T cells during development of EAE.
Furthermore, total IL-17A and IL-17F gene expression in the
spleen was significantly (p < 0.05) lower in Tcrd/ mice
compared with WT mice with EAE (Figure 5C), suggesting that
gd T cells make a major contribution to IL-17 production in vivo
during development of EAE.
We next examined the role of gd T cells activated by IL-1b and
IL-23 in the induction of EAE. Il1r1/ mice were substantially
more resistant to EAE than wild-type mice (Figure 5D). Transfer
of CD3+ T cells from naive C57BL/6 mice to Il1r1/mice before
immunization with MOG and complete Freund’s adjuvant (CFA)
enhanced susceptibility to EAE, but depletion of gd T cells
from the transferred CD3+ T cells reduced their capacity to
confer susceptibility to EAE. Transfer of autoantigen-specific
Th17 cells has been shown to transfer EAE to naive mice
Immunity
gd T Cells Are an Important Source of Innate IL-17(Langrish et al., 2005). We found that lymph node and spleen
cells from mice with EAE stimulated with MOG in the presence
of IL-1 and IL-23 induced EAE after transfer to recipient mice
(Figure 5E). These cultured cells included IL-17-secreting gd
T cells as well as CD4+ T cells, but not NK cells (data not shown).
CD4+ and CD8+ with gd T cells purified from the cultured cells
also induced mild EAE, but purified CD4+, CD4+ and CD8+, or
gd T cells alone failed to transfer EAE (Figures 5E and 5F). Collec-
tively, our data suggest that IL-17-producing gd T cells, as well
as CD4+ T cells, infiltrate the CNS of mice with EAE and that
both of these cell types are required for optimal development
of EAE.
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Figure 4. A High Frequency of IL-17-Secreting gd T
Cells Infiltrate the CNS of Mice at the Onset of EAE,
which Correlates with IL-1b and IL-23p19 mRNA
Expression
EAE was induced in C57BL/6 mice. Brain mononuclear cells
from naive mice and mice 7, 10, 14, and 21 days after induc-
tion of EAE, were stained for intracellular IL-17 or IFN-g and
surface CD45, CD3, and gd TCR or CD4. Representative dot
plots of IL-17 or IFN-g-secreting gd T cells (A) or IL-17 or
IFN-g-secreting CD4+ T cells (B) on day 10 are shown. (C)
shows the mean percentage and absolute number of IL-17
or IFN-g-secreting gd T cells for five control (Cont.) mice and
five mice at 7, 10, 14, and 21 days after induction of EAE;
*p < 0.05, **p < 0.01, ***p < 0.001 versus control. As shown
in (D), brain mononuclear cells from mice 10 days after induc-
tion of EAE were stained for intracellular IL-17 and for surface
gd TCR, Vg4, Vg5, and Vd6.3/2. Numbers refer to percentages
of total gd T cells. As shown in (E), IL-17A, IL-1b, and IL-23p19
mRNA expression was evaluated in the brain (cortex) by real-
time PCR normalized to 18 s rRNA and relative to naive control
mice. **p < 0.01, versus control. Dot plots are representative of
five individual mice per group. Data are representative of three
experiments. All error bars represent mean ± SD.
gd T Cells Activated with IL-1 and IL-23
Promote IL-17 Production by CD4+ T Cells
Our findings suggest that gd T cells, as well as
directly contributing to pathogenic cytokine
production, may also augment IL-17 production
by autoantigen-specific Th17 cells in vivo. We
sought to provide further evidence for this hypoth-
esis. Consistent with the data in Figure 3, we found
that spleen cells from Tcrd/ mice failed to
secrete IL-17 in response to IL-1b and IL-23, in
the absence of anti-CD3 (Figure 6A). Addition of
anti-CD3 (required to activate IL-17 production
by Th17 cells) substantially augmented IL-17
production induced by IL-1b and IL-23 or either
cytokine alone. However, this was also signifi-
cantly (p < 0.001) reduced in spleen cells from
Tcrd/ mice (Figure 6A), suggesting that gd
T cells can augment IL-17 production from ab
T cells. This was confirmed by the demonstration
that IL-17 production by CD4+ T cells stimulated
with anti-CD3 and anti-CD28 was significantly (p
< 0.001) enhanced by addition of gd T cells that
had been prestimulated with IL-1b and IL-23 (and
washed to remove IL-1b and IL-23), but not with
gd T cells stimulated with medium only (Figure 6B). Addition of
DCs to the cultures enhanced the ability of IL-1b- and IL-23-acti-
vated gd T cells to promote IL-17 production by CD4+ T cells
stimulated with anti-CD3 and anti-CD28 (Figure 6C). These find-
ings suggest that IL-1b- and IL-23-activated gd T cells promote
IL-17 production by ab T cells, either by acting directly on the
CD4+ T cells and/or indirectly by promoting cytokine production
from DCs.
In order to examine the relative role of soluble factors
produced by gd T cells activated with IL-1b and IL-23 in
promoting IL-17 production by CD4+ T cells, we stimulated gd
T cells with IL-1b and IL-23 overnight, then washed andImmunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc. 335
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gd T Cells Are an Important Source of Innate IL-17recultured them for an additional 48 hr. Supernatants were
recovered at 72 hr and used for CD4+ T cell stimulation. Super-
natants from gd T cells that had been stimulated with IL-1b
and IL-23 induced IL-17A and IL-17F mRNA expression by
CD4+ T cells (Figure 6D). These findings demonstrate that gd
T cells activated with IL-1b and IL-23 can promote anti-CD3-
induced IL-17 production by CD4+ T cells, at least in part through
the release of soluble factors. Given that binding of ligands to aryl
hydrocarbon receptors (AhRs) expressed on Th17 cells induces
IL-17 production (Veldhoen et al., 2009), we assessed the
possible role of AhR signaling in IL-1- and IL-23-induced IL-17
production. We found that an AhR antagonist, CH-223191, did
not suppress IL-17 production by spleen cells stimulated with
IL-1 and IL-23 in the presence or absence of anti-CD3
(Figure S4).
We have shown that IL-1b and IL-23 can induce IL-17 and
IL-21 expression in gd T cells, and it has already been reported
that IL-21 together with TGF-b or IL-23 can stimulate IL-17
production by CD4+ T cells (Korn et al., 2007; Nurieva et al.,
2007; Zhou et al., 2007). However, it is also possible that gd
T cell-derived IL-17 may promote further IL-17 production by
Th17 cells. Therefore, we examined the roles of IL-21 and
IL-17 in gd T cell-induced IL-17 production by CD4+ T cells.
We found the induction of IL-17A and IL-17F mRNA expression
in CD4+ T cells by supernatants from gd T cells activated with
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Figure 5. gd TCells Cooperate with Conven-
tional T Cells in the Development of EAE
(A and B) EAE was induced in C57BL/6 or Tcrd/
mice.
(A) Mice were observed daily for clinical symptoms
of EAE. *p < 0.05 versus Tcrd/.
(B) Mice were sacrificed and lymph node cells
stimulated for 3 days with MOG peptide, medium,
or PMA and anti-CD3. IL-17 concentrations in
supernatants were determined by ELISA. **p <
0.01 and ***p < 0.001 versus C57BL/6.
(C) IL-17A and IL-17F mRNA expression was eval-
uated in spleen tissue by real-time PCR normalized
to 18 s rRNA and relative to naive control mice. *p <
0.05 versus WT with EAE.
(D) EAE was induced in C57BL/6 or Il1r1/ mice.
In addition, CD3+ T cells or CD3+ T cells depleted
of gd T cells from WT mice were transferred into
Il1r1/ mice 24 hr before induction of EAE. Mice
were observed daily for clinical signs of EAE; n = 5.
(E and F) Spleen and lymph node cells from mice
with EAE were stimulated in vitro with MOG or
MOG + IL-1 + IL-23. After 3 days, unseparated
cells, CD4+ T cells, or gd T cells purified from the
cultures (E) or CD4+ and CD8+ or CD4+ and CD8+
plusgdT cells (F) were transferred to naive recipient
mice. Mice were observed for symptoms of EAE.
Data are representative of two to three independent
experiments. All error bars represent mean ± SD.
IL-1b and IL-23 was inhibited by addition
of anti-IL-17 or anti-IL-21; the greatest
inhibition of IL-17 expression was
observed when both antibodies were
added to the cultures (Figure 6D). These
findings suggest that gd T cell-derived IL-17 and IL-21 augment
IL-17 production by Th17 cells.
CD4+ T Cells and DCs Express IL-17R
and Respond to IL-17
In order to provide further evidence that IL-17 may amplify its
own production either by acting directly on CD4+ T cells or indi-
rectly on DC,we examined expression of IL-17R and responsive-
ness of these cells to IL-17. We first showed that CD4+ T cells
from naive mice express IL-17R mRNA and the expression
was stronger than that observed for lung or spleen (Figure 7A),
tissues previously shown to express IL-17R. We next used
IL-17 mRNA expression to examine autocrine production of
IL-17 by CD4+ T cells and found that recombinant IL-17A
induced IL-17A and IL-17F mRNA expression in CD4+ T cells
(Figure 7B). We also examined the effect of IL-21 and found
that it did not induce IL-17 or amplify IL-17-induced IL-17
expression by CD4+ T cells (not shown). However, IL-21 did
enhance IL-23-induced IL-17A and IL-17F expression by CD4+
T cells (Figure 7C).
DCs were also found to express IL-17R, which was enhanced
after stimulation with TLR agonists (Figure 7D). DCs secrete
IL-23 after stimulation with low concentrations of IL-17 (Fig-
ure 7E), and this was inhibited by coincubation with IL-17RFc
(Figure S5). Furthermore, IL-17-induced IL-23 production was336 Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc.
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gd T Cells Are an Important Source of Innate IL-17enhanced by costimulation with a TLR agonist (Figure 7F). More-
over, LPS-induced IL-12p40, IL-1b, and IL-6 production by DC
was substantially enhanced by IL-17 (Figure 7F). In addition,
IL-17 induced TGF-b and CCL2 mRNA expression and substan-
tially augmented LPS-induced IL-1b, IL-6, CCL2, and CXCL10
mRNA expression (Figure 7G). Addition of IL-17RFc reduced
expression to that induced with LPS alone, confirming that the
effect of IL-17wasmediated via IL-17R and not due to a contam-
inant in the IL-17 preparation.
We next examined an autocrine role for IL-17 in vivo by admin-
istering anti-IL-17R or IL-17 during the induction of EAE. We
found a significant (p < 0.05) reduction in antigen-specific
IL-17 production in lymph nodes, but not spleen, of mice treated
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Figure 6. gd T Cells Activated with IL-1b and IL-23 Promote IL-17
Production from CD4+ T Cells
(A) Spleen cells from C57BL/6 and Tcrd/mice were stimulated as indicated
for 3 days and IL-17 concentrations in supernatants quantified by ELISA.
***p < 0.001 versus WT.
(B andC) gd T cells were incubated with IL-1b and IL-23 ormedium alone. After
3 days, cells were washed and added to purified CD4+ T cells with and without
anti-CD3 and anti-CD28 (B) or anti-CD3 and DCs (C). After an additional
3 days, supernatants were removed and IL-17 concentrations quantified by
ELISA. ***p < 0.001 versus no anti-CD3, +++p < 0.001 gd (medium) versus gd
(IL-1b + IL-23), ###p < 0.001, versus without DCs.
(D) Purified CD4+ T cells were stimulated with anti-CD3 and anti-CD28 and
medium only or with supernatants from gd T cells stimulated with IL-1b + IL-
23 (washed on day 1), with or without anti-IL-17, anti-IL-21, or both antibodies.
IL-17A and IL-17F mRNA expression was evaluated by real-time PCR normal-
ized to 18 s rRNA and relative to CD4+ T cells stimulated with medium only.
*p < 0.05 and **p < 0.01, with versus without antibody. Data are representative
of three independent experiments. All error bars represent mean ± SD.with anti-IL-17R (Figure S6A). Moreover, anti-IL-17R treatment
suppressed IL-17A mRNA expression in the spinal cord
(Figure S6B). The reduction in IL-17 was associated with slower
onset of EAE in these mice (Figure S6C). Conversely, we found
that administration of IL-17 with CFA andMOG resulted in earlier
onset of EAE and more pronounced clinical scores early in
disease (Figure S6D).
These data suggest that early IL-17 has a positive rather than
negative feedback role on IL-17 production, especially early in
EAE. Collectively, our findings suggest that IL-1b and IL-23
promote innate IL-17 production by gd T cells, which amplifies
IL-17 production by CD4+ T cells, either by interacting directly
with CD4+ T cells or indirectly with DC to enhance production
of innate cytokines that drive the induction and expansion of
Th17 cells. Thus, gd T cells, as well as making a substantial
contribution to the overall pool of IL-17 in vivo, may act as an
early source of IL-17 and IL-21 to amplify Th17 cell responses.
DISCUSSION
The results of this study demonstrate that gd T cells are an impor-
tant source of innate IL-17 and that these cells constitutively
express IL-23R and also secrete IL-21 and IL-22. The present
study also reveals a new mechanism of IL-23 and IL-1-induced
IL-17 production. We demonstrate that IL-23 in combination
with IL-1b promotes IL-17, IL-21, and IL-22 expression by gd
T cells in the absence of additional signals. Finally, we demon-
strate that gd T cells may act in an amplification loop to promote
IL-17 production by Th17 cells.
The transcription factor RORgt, which has been associated
with the development of CD4+ Th17 cells (Ivanov et al., 2006),
is also expressed by NKT cells (Rachitskaya et al., 2008) and
CD4+CD3 lymphoid tissue inducer (LTi)-like cells (Takatori
et al., 2009). We demonstrated constitutive expression of RORgt
in gd T cells, which was enhanced by IL-23. Furthermore, IL-23
induced IL-17A, IL-17F, and IL-22 expression, which was
enhanced by IL-1b. Interestingly, we found that IL-21, which is
induced in naive CD4+ T cells by stimulation with anti-CD3,
anti-CD28, and IL-6 or IL-6 and TGF-b (Korn et al., 2007), was
also expressed at very large amounts in gd T cells, but not by
gd T cell-depleted CD3+ T cells, after stimulation with IL-1b
and IL-23.
In addition to the roles of IL-6 and TGF-b in promoting the
differentiation of Th17 cells, there are firmly established roles
for IL-23 and IL-1 in promoting IL-17 production and mediating
the development of autoimmune diseases. A major function of
IL-23 in autoimmunity and infection is considered to involve
promoting IL-17 production from memory CD4+ T cells (Higgins
et al., 2006; van Beelen et al., 2007). However, studies in an EAE
model, involving adoptive transfer of T cells into Il23a/ mice,
showed that IL-23 played a critical role in the development but
not in the effector function of encephalitogenic T cells (Thakker
et al., 2007). In an EAU model, neutralization of IL-23 reduced
IL-17 production and attenuated EAU when administered imme-
diately before and after induction of disease, but not at the
effector stage of the disease (Luger et al., 2008). These findings
are consistent with the suggestions that IL-23 may be central to
differentiation rather than expansion or survival of pathogenic
Th17 cells (McGeachy and Cua, 2008; Wilson et al., 2007).Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc. 337
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gd T Cells Are an Important Source of Innate IL-17Furthermore, studies in a colitis model have suggested that IL-23
can promote innate IL-17 production, but did not define the cell
population involved (Hue et al., 2006). It has also been reported
that stimulation of peritoneal exudate cells with IL-23, but not by
IL-6 and TGF-b, induced IL-17 production by gd T cells (Shibata
et al., 2007). Our study demonstrates a requirement for IL-1 and
shows that IL-23 and IL-1b promote innate IL-17 production from
gd T cells and provides an alternative mechanism whereby IL-23
and IL-1b may contribute to host defense and autoimmune
inflammation.
It has previously been reported that unconventional T cells,
especially NKT cells, express the IL-23R and secrete IL-17
during infection or inflammation or when activated in vitro with
anti-CD3 and IL-23 or with the synthetic ligand a-galactosylcer-
amide (Lockhart et al., 2006; Rachitskaya et al., 2008; Shibata
et al., 2007). Furthermore, it has recently been demonstrated
that IL-23 can promote innate IL-17 and IL-22 production by
LTi-like cells when stimulated in vitro or in vivo with zymosan
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Figure 7. IL-17A Induces IL-17A and IL-17F
Production from CD4+ T Cells and Enhances
TLR-Induced IL-1b and IL-23 Production
from DCs
(A) IL-17RmRNAexpressionwasevaluated inCD4+
T cells, lung, spleen, and control tissue (Cont; liver)
from naive mice by real-time PCR normalized to
18 s rRNA and relative to control tissue.
(B) Purified CD4+ T cells from C57BL/6 mice were
stimulated with anti-CD3 in the presence of IL-17
or medium only (Med), and IL-17A and IL-17F
mRNA expression was evaluated by real-time
PCR normalized to 18 s rRNA.
(C) Purified CD4+ T cells from C57BL/6 mice were
stimulated with anti-CD3 and IL-21, IL-23, or both
cytokines or with medium only (Med). IL-17A and
IL-17F mRNA expression was evaluated by real-
time PCR normalized to 18 s rRNA and expressed
relative to medium only.
(D) BMDC were stimulated with medium (Med)
only, LPS, or CpG, and IL-17R mRNA expression
was evaluated by real-time PCR normalized to
18 s rRNA and relative to a control (Cont.; liver).
(E) BMDC were stimulated with IL-17 or medium
only. After 24 hr, IL-23 production in supernatants
was quantified by ELISA.
(F) DCs were stimulated with LPS, IL-17, LPS +
IL-17, or medium alone. After 24 hr, supernatants
were removed and IL-23, IL-1b, IL-12p40, and
IL-6 concentrations were quantified by ELISA.
(G) DCs were stimulated with LPS alone or with
IL-17 in the presence or absence of IL-17RFc. After
24 hr, TGF-b, IL-1b, IL-6, CCL2, and CXCL10
mRNA was evaluated by real-time PCR normalized
to 18 s rRNA and relative to DC stimulated with
medium only. Data are representative of at least
two independent experiments. All error bars repre-
sent mean ± SD.
(Takatori et al., 2009). It has also been re-
ported that gd T cells and other non CD4+
or CD8+ T cells are amajor source of IL-17
during infection with M. tuberculosis
(Lockhart et al., 2006). Vd1+ cells have
been shown to accumulate at the site of E. coli infection, where
they promote neutrophil recruitment (Shibata et al., 2007). More-
over, there is evidence that gd T cells may have a pathogenic role
in CIA (Roark et al., 2007). Our study demonstrates that gd T cells
infiltrate the CNS during the development of EAE, and a very high
frequency of these cells secretes IL-17.We detected Vg4+, Vg5+,
and Vd6.3/2+ cells, but consistent with the CIA studies (Roark
et al., 2007), the dominant IL-17-secreting gd T cells were
Vg4+. A much smaller number of gd T cells in the CNS of mice
with EAE secreted IFN-g. In contrast, a similar frequency of
IL-17 and IFN-g-secreting CD4+ T cells was detected in the
CNS at the onset of EAE, and although the absolute numbers
are greater, a lower percentage of CD4+ than gd T cells secreted
IL-17. A high frequency of IL-17-secreting gd T cells has also
been reported in draining lymph nodes 0–4 days after immuniza-
tion with MOG and CFA, which preceded the generation of
MOG-specific CD4+ T cells (Jensen et al., 2008). Taken together
with our findings, this suggests that IL-17-secreting gd T cells338 Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc.
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gd T Cells Are an Important Source of Innate IL-17may play a pathogenic role early in disease and may then influ-
ence the generation of Th17 cells. Consistent with this, studies
in humans have described an accumulation of gd T cells in acute
MS lesions (Wucherpfennig et al., 1992) and clonal expansion of
gd T cells in cerebrospinal fluid of MS patients with recent-onset
disease (Shimonkevitz et al., 1993).
Evidence that the infiltrating IL-17-secreting gd T cells may
have a pathogenic function in EAE is provided by our findings,
which are consistent with previous reports (Jensen et al., 2008;
Spahn et al., 1999) that clinical symptoms are attenuated in
Tcrd/ mice. Furthermore, we found that depletion of gd
T cells from CD3+ T cells from naive WT mice prior to transfer
to Il1r1/ mice reduced their ability to confer susceptibility to
EAE. In addition, we found that gd T cells were required for trans-
fer of EAE with cultured CD4+ and CD8+ T cells stimulated with
MOG, IL-1b, and IL-23. As well as contributing to the pool of
IL-17 produced locally in the CNS during development of EAE,
our data suggest that gd T cells may also play a cooperative
role with conventional autoantigen-specific ab T cells in medi-
ating autoimmune disease. Further evidence for this hypothesis
was provided by the observation that attenuation of EAE in
Tcrd/ mice correlated with a substantial reduction in total
IL-17 mRNA expression, but also in MOG-specific IL-17, which
is primarily produced by CD4+ T cells.
Our study revealed that cytokines produced by gd T cells in
response to stimulation with IL-1 and IL-23 promote IL-17
expression by CD4+ T cells. Supernatants from gd T cells acti-
vated with IL-1 and IL-23 (washed and recultured for removal
of IL-1 and IL-23) promoted IL-17A and IL-17FmRNA expression
by CD4+ T cells after costimulation with anti-CD3 and anti-CD28.
Furthermore, this enhancement of IL-17 mRNA expression was
inhibited by coculture with anti-IL-21 and anti-IL-17. Because
we also found that IL-21 was expressed by gd T cells after stim-
ulation with IL-1 and IL-23, but not either cytokine alone, these
findings suggest that IL-21 may in part mediate the effect of gd
T cells on IL-17 production by CD4+ T cells. This conclusion
is consistent with the recent demonstration that IL-21 plays a
critical role in IL-17 production by naive CD4+ T cells (Korn
et al., 2007; Nurieva et al., 2007; Zhou et al., 2007). The induction
of IL-17A and IL-17F mRNA expression in CD4+ T cells by super-
natants from gd T cells that had been stimulated with IL-1b and
IL-23 was also inhibited by anti-IL-17. This was consistent with
our demonstration that CD4+ T cells expressed endogenous
IL-17R and responded to IL-17 by enhancing expression of IL-
17A and IL-17F mRNA. However, it has been reported that
IL-17-producing T cells are enhanced in the spleen or liver, but
not the lymph node, of Il17ra/ mice and that IL-17F can
suppress IL-17A production by CD4+ T cells (Nagata et al.,
2008; Smith et al., 2008). We found that treatment with anti-IL-
17R early in EAE reduced IL-17 production and attenuated
disease, whereas administration of IL-17 with MOG and CFA
enhanced the onset of EAE. Although an autocrine or paracrine
role for IL-17 in modulating IL-17 production is still unclear, our
findings suggest that early IL-17 has a positive rather than nega-
tive feedback role for induction of IL-17, especially early in EAE.
This is consistent with our conclusions that early IL-17 from gd
T cells may promote the induction or activation of Th17 cells.
Our study also reveals an additional mechanism whereby
IL-17-producing gd T cells may amplify Th17 responses. Addi-tion of DCs enhanced the ability of gd T cells activated with
IL-1 and IL-23 to promote IL-17 production by CD4+ T cells.
We found that DCs also expressed IL-17R and secreted IL-23
in responses to IL-17, which was enhanced by LPS and blocked
by addition of IL-17RFc. Furthermore, DCs expressed IL-1b,
IL-6, TGF-b, CCL2, and CXCL10 in response to IL-17 alone or
in synergy with a TLR agonist. These findings demonstrate that
gd T cell-derived IL-17 promotes further IL-17 production by
Th17 cells, both directly by interacting with IL-17R on CD4+
T cell and indirectly by enhancing the production of IL-23 and
other cytokines and chemokines from DCs that promote the
development, expansion, and recruitment of Th17 cells.
Our study provides evidence that gd T cells, through IL-17 and
IL-21 production, may help to mediate the effects of IL-23 and
IL-1b in promoting the development and expansion of Th17 cells.
Thus, analogous to the role of NK cells in amplifying the effects of
IL-12 on Th1 cells, gd T cells may act to amplify the induction of
Th17 cells. Our findings shed new light on the potential role of gd
T cells in host defense and inflammatory diseases, provide
important new information on the pathogenic role of IL-23 and
IL-1b, and underline the importance of targeting these cytokines
in the development of new therapeutic interventions against
autoimmune diseases.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (Harlan UK), Il1r1/, and TCR d mutant mice, defective in gd TCR
expression (Tcrd/) on C57BL/6 backgrounds (Jackson Labs), were bred
under SPF conditions. Animal experiments and maintenance were approved
by the university’s ethics committee and the Irish Department of Health.
Induction and Assessment of EAE
C57BL/6, Tcrd/, and Il1r1/ mice were immunized subcutaneously (s.c.)
with 150 mg of MOG peptide 35-55 (Cambridge BioSciences) emulsified in
CFA containing 4 mg/ml heat-killed MTB (Chondrex). Mice were injected intra-
peritoneally (i.p.) with 500 ng pertussis toxin (PT; Kaketsuken) on days 0 and 2.
In some experiments, purified CD3+ T cells or CD3+ T cells depleted of gd
T cells from naive mice were injected intravenously (i.v.) 24 hr prior to the
induction of EAE. Alternatively, EAE was induced by transfer of spleen and
lymph node cells frommicewith EAE (day 21) after culture for 3 days with either
MOGorMOG, IL-1b, and IL-23 or by transfer of CD4+ or gd T cells purified from
these cultures. Mice were observed for clinical signs of disease daily. Disease
severity was recorded as follows: grade 0, normal; grade 1, limp tail; grade 2,
wobbly gait; grade 3, hind limb weakness; and grade 4, hind limb paralysis.
T Cell Sorting and Culture
CD3+, CD4+, and CD4+CD62LhiCD44lo T cells were purified from spleens of
C57BL/6 mice with mouse T cell subset column kits (R&D). gd T cells were
sorted by FACS (Dako Moflo) or MACS. Cells were cultured with IL-1b
(10 ng/ml), IL-23 (10 ng/ml), TGF-b (10 ng/ml), or IL-6 (20 ng/ml), in the absence
or presence of anti-CD3 (1 mg/ml) and anti-CD28 (10 mg/ml). After 24–72 hr,
IL-17 concentrations in supernatants were determined by ELISA (R&D).
Dendritic Cells
Mouse bone-marrow derived immature DCs were generated as described
(Higgins et al., 2006). DCs were cultured with MTB (10–50 mg/ml; Chondrex),
LPS (10–100 ng/ml; Alexis), CpG (20 mg/ml), muramyl dipeptide (20 mg/ml),
peptidoglycan (25 mg/ml), or combinations thereof, with and without IL-1Ra
(10 mg/ml; Anakinra) and anti-IL-23R (10 mg/ml; R&D) or with IL-17 (0.1–
10 ng/ml; R&D) in the presence and absence of IL-17RFc (2 mg/ml; R&D). After
24 hr, supernatants were tested for IL-1b, IL-12p70 (R&D), IL-23 (eBioscien-
ces), IL-6, and IL-12p40 (BD PharMingen) concentrations by ELISA.Immunity 31, 331–341, August 21, 2009 ª2009 Elsevier Inc. 339
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Spleen cells (2 3 106 cells/ml) from C57BL/6 mice were incubated for 72 hr
with medium or cytokines and for the last 6 hr in the presence of brefeldin A
(5–10 mg/ml). Alternatively, mononuclear cells were isolated by percoll density
centrifugation from the brain of mice perfused with PBS and stimulated with
PMA (10 ng/ml) and ionomycin (1 mg/ml) with brefeldin A (5 mg/ml). Cells
were washed and blocked with Fcg blocker (BD PharMingen; 1 mg/ml) before
extracellular staining for surface CD3, gd TCR, Vg4, Vg5, Vd6.3/2, CD4, or
CD8. Cells were then fixed and permeabilized (Fix and Perm Cell Permeabili-
zation Kit; Caltag) and stained intracellularly for IL-17 or IFN-g. Flow cytometric
analysis was performedwith either a BD FACSCaliber and Summit software or
a Cyan ADP Flow Cytometer (Dako Cytomation) with FloJo software, with
gating set on isotype controls or FMOs, respectively.
Real-Time PCR
gd T cells or gd-depleted T cells were purified from spleens of C57BL/6 mice
and incubated for 48 hr with IL-1b (10 ng/ml), IL-23 (10 ng/ml), both, or medium
alone. CD4+ T cells were stimulatedwith supernatants from gd T cells activated
with IL-1 and IL-23, in the presence or absence of anti-IL-17 and anti-IL-21
(10 mg/ml) or with recombinant IL-17 (10 ng/ml; R&D). DCs were stimulated
with medium only, LPS, or CpG. RNA was harvested from gd T cells,
gd-depleted T cells, CD4+ T cells, DCs, spinal cord, lung, liver, or spleen tissue
with the Trizol (Invitrogen)/chloroform method; this process was followed by
reverse transcription into cDNA with a QuantiTect Reverse Transcription Kit
(QIAGEN). Real-time PCR for the detection of Il17a (Mm00439619_m1), Il17f
(Mm00521423_m1), Il23r (Mm00519942_m1), Rorc (Mm01261022_m1), Il21
(Mm00517640_m1), Il22 (Mm00444241_m1), Il17r (Mm00434214_m1), Tgfb1
(Mm00441724_m1), Ccl2 (Mm00441242_m1), Cxcl10 (Mm99999072_m1),
Il23a (Mm00518984_m1), and Il1b (Mm00434228_m1) mRNA was performed
with predesigned Taqman gene expression assays (Applied Biosystems).
Expression was normalized to 18s ribosomal RNA. Samples were assayed
on an Applied Biosystems 7500 Fast Real Time PCR machine.
Antigen-Specific IL-17 Production
Spleen and lymph node cells (1 3 106 cells/ml) were stimulated with MOG
(12.5, 25 and 50 mg/ml) or PMA (Sigma; 20 ng/ml) and anti-CD3 (1 mg/ml),
and IL-17 concentrations in supernatants were determined by ELISA (R&D).
Statistical Analysis
Data were compared by two-tailed Student t test, Wilcoxon Rank test, and by
one-way ANOVA.Where significant differences were found, the Tukey-Kramer
multiple comparisons test was used for identifying differences between indi-
vidual groups.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found with this article online
at http://www.cell.com/immunity/supplemental/S1074-7613(09)00327-6.
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